[en] Purpose: Randomized trial LNH93-3 was conducted on patients who had poor-prognosis aggressive lymphoma and were younger than 60 years with two to three factors of the age-adjusted International Prognostic Index to evaluate the benefit of early high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT). Patients and Methods: Patients were randomized between doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) chemotherapy followed by sequential consolidation and an experimental shortened treatment consisting of three cycles with escalated doses of cyclophosphamide, epirubicin, vindesine, bleomycin, and prednisone and collection of peripheral-blood stem cells. On day 60, HDT was administered with 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, cytarabine, and melphalan followed by ASCT. Results: Eligible patients (n = 370) with aggressive lymphoma were analyzed. For ACVBP (181 patients) and HDT (189 patients), respective complete remission rates were 64% and 63%. With a median follow-up of 60 months, 5-year overall survival and event-free survival for ACVBP and HDT were 60% +/- 8% and 46% +/- 8% (P = .007) and 52 +/- 8% and 39 8% (P = .01), respectively. Survival was independently affected by age greater than 40 years (P = .0003), T-cell phenotype (P = .009), bone marrow involvement (P = .003), and HDT treatment group (P = .04). Conclusion: Early HDT with ASCT in high-risk patients was inferior to the ACVBP chemotherapy regimen. These results indicate that the received dose-intensity before HDT was too low when compared with ACVBP and HDT and was given too early. (C) 2002 by American Society of Clinical Oncology.
Disciplines :
Oncology
Author, co-author :
Gisselbrecht, C.
Lepage, E.
Molina, T.
Quesnel, B.
Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale
Lederlin, P.
Coiffier, B.
Tilly, H.
Gabarre, J.
Guilmin, F.
Hermine, O.
Reyes, F.
Language :
English
Title :
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma
Publication date :
15 May 2002
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
Lippincott Williams & Wilkins, Philadelphia, United States - Pennsylvania
Fisher R.I., Gaynor E.R., Dahlberg S. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006.
Philip T., Guglielmi C., Hagenbeek A. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545.
Shipp M.A., Abeloff M.D., Antman K.H. (1999) International Consensus Conference on High-Dose Therapy with Hematopoietic Stem-Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury. J Clin Oncol 17:3128-3135.
Gulati S.C., Shank B., Black P. (1988) Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 6:1303-1313.
Nademanee A., Schmidt G.M., O'Donnel M.R. (1992) High-dose chemotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study. Blood 80:1130-1134.
Freedman A.S., Takvorian T., Neuberg D. (1993) Autologous bone marrow transplantation in poor-prognosis intermediate-grade and highgrade B-cell non-Hodgkin's lymphoma in first remission: A pilot study. J Clin Oncol 11:931-936.
Sierra J., Conde E., Montserrat E. (1993) Autologous bone marrow transplantation for non-Hodgkin's lymphoma in first remission. Blood , letter; 81:1968.
Pettengel R., Radford J.A., Morgenstern G.R. (1996) Survival benefit from high-dose therapy with autologous blood progenitor cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 14:586-592.
Cortelazzo S., Rossi A., Bellavita P. (1999) Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). Ann Oncol 10:427-432.
Vitolo U., Cortellazzo S., Liberati A.M. (1997) Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high risk diffuse large-cell lymphoma. J Clin Oncol 15:491-498.
Haioun C., Lepage E., Gisselbrecht C. (2000) Survival benefit of high dose therapy in poor risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A Groupe d'Etude des Lymphomes de 1'Adulte study. J Clin Oncol 18:3025-3030.
Santini G., Salvagno L., Leoni P. (1998) VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 16:2796-2802.
Gianni A.M., Bregni M., Siena S. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297.
Verdonck L.F., Van Putten W.L.J., Hagenbeek A. (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051.
(1993) The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994.
Coiffier B., Gisselbrecht C., Herbrecht R. (1989) LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026.
Tilly H., Mounier N., Lederlin P. (2000) Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH87- 1 study. J Clin Oncol 18:1309-1315.
Tilly H., Lepage E., Coiffier B. (2000) A randomized comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: The LNH93-5 study. Blood , abstract 3596; 96:11.
Gisselbrecht C., Lepage E., Morel P. (1996) Intensified phase including autologous peripheral stem cell transplantation does not improve response rate and survival in lymphoma with at least 2 adverse prognostic factors when compared to ACVB regimen. Blood , (ASH, 38th annual meeting. Orlando. FL, December 6-10), abstract 470; 88:10.
Stansfeld A.G., Diebold J., Noel H. (1998) Updated Kiel classification for lymphomas. Lancet , letter; 1:292-293.
Harris N.L., Jaffe E.S., Diebold J. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849.
Gisselbrecht C., Gaulard P., Lepage E. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 92:76-82.
Langouët A.M., Brice P., Simon D. (2001) Factors affecting hematopoietic recovery after autologous peripheral blood progenitorcell transplantation in aggressive non-Hodgkin's lymphoma: A prospective study of 123 patients. Hematol J 2:81-86.
Cheson B.D., Horning S.J., Coiffier B. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253.
Kaplan E.L., Meier P. (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
Mantel N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170.
Hess K.R., Serachitopol D.M., Brown B.W. (1999) Hazard function estimators: A simulation study. Stat Med 18:3075-3088.
Cox D.R. (1972) Regression models and life tables. J R Stat Soc (B) 34:187-202.
Launchbury A.P., Habboubit N. (1993) Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19:197-228.
Jacquy C., Sorée A., Lambert F. (2000) A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: One-half of patients significantly mobilize malignant cells. Br J Haematol 110:631-637.
Mounier N., Haioun C., Cole B.F. (2000) Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Blood 95:3687-3692.
Haioun C., Lepage E., Gisselbrecht C. (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol , Groupe d'Etude des Lymphomes de l'Adulte; 15:1131-1137.
Lepage E., Gisselbrecht C., Haioun C. (1993) Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to the LNH- 87 protocol. Ann Oncol 4:651-656.
Gisselbrecht C., Haioun C., Lepage E. (1997) Placebo controlled phase III trial of lenograstim (glycosylated recombinant human G-CSF) in aggressive non-Hodgkin's lymphoma. Leuk Lymph 25:289-300.
Kluin-Nelemans H.C., Zagonel V., Anastasopoulou A. (2001) Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 93:22-30.
Kaiser U., Uebelacker I., Birkmann J. (1999) High dose therapy with autologous stem cell transplantation in aggressive NHL: Results of a randomized multicenter study. Blood , abstract 2716; 94:671.
Coiffier B., Lepage E., Brière J. (2002) CHOP plus rituximab with CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma: A Groupe d'Etude des Lymphomes de l'Adulte study. N Engl J Med 346:235-242.
